AKT1 and small cell lung carcinoma: Talazoparib, which has an approximately 10-fold lower IC50 in SCLC than olaparib or rucaparib, induced a similar response in H69 cells, as exhibited by increased p-AKT T673 and p-S6 S240,244 following treatment (S1 Fig).